Study type: Human research · Status: Verified against declared source

Cerebrolysin as an Early Add-on to Reperfusion Therapy: Risk of Hemorrhagic Transformation after Ischemic Stroke (CEREHETIS), a prospective, randomized, multicenter pilot study.

BMC neurology · 2023

Study scale: Trial Registration Number: ISRCTN87656744.

Abstract only: Open source record

Product or molecular entity relationships

Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Our primary goal was the assessment of the HT rate.

Methods

All participants were treated in the hospital settings since inpatient length of stay was at least 14 days according to the national insurance standard for patients with AIS.

Scale or participants

Trial Registration Number: ISRCTN87656744.

Key findings

Cerebrolysin treatment resulted in a substantial decrease of the symptomatic HT rate with an odds ratio (OR) of 0.248 (95% CI: 0.072–0.851; p = 0.019).

Limitations and uncertainty

Cerebrolysin treatment resulted in a substantial decrease of the symptomatic HT rate with an odds ratio (OR) of 0.248 (95% CI: 0.072–0.851; p = 0.019).

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.